Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation

In 2015, liposomal formulation of irinotecan (ONIVYDE) has been approved by FDA and widely applied in the treatment of pancreatic cancer. ONIVYDE is a novel liposome formulation, entrapping CPT-11 in the aqueous core of vesicles using a modified gradient loading method. Due to toxicity concerns, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenqian, Yang, Zimeng, Liu, Jieru, Liu, Dan, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032223/
https://www.ncbi.nlm.nih.gov/pubmed/32104495
http://dx.doi.org/10.1016/j.ajps.2018.08.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032223/
https://www.ncbi.nlm.nih.gov/pubmed/32104495
http://dx.doi.org/10.1016/j.ajps.2018.08.003

Ejemplares similares